Table 1 Comparison of clinical and laboratory features between 304 AML patients stratified by Stellae-123 model derived from the BeatAML cohort.
Variable [median (range) or n (%)] | Total | Stellae-123 Risk Group | P value | ||
|---|---|---|---|---|---|
Favorable (n = 101) | Intermediate (n = 101) | Adverse (n = 102) | |||
Age (years) | 46 (18–86) | 44 (18–78) | 46 (18–86) | 47 (18–84) | NS |
Sex, Male | 164 (53.9) | 50 (49.5) | 55 (54.5) | 59 (57.8) | NS |
Laboratory data | |||||
White Blood Cell (× 109/L) | 34.2 (1.1–406) | 38.5 (1.5–324) | 35.8 (1.1–406) | 30.1 (1.2–341) | NS |
Hemoglobin (g/dL) | 8.0 (2.7–13.6) | 8.3 (2.7–13.6) | 8.1 (4.2–13.6) | 7.5 (3.7–13.2) | NS |
Platelet (× 109/L) | 45 (3–751) | 41 (5–203) | 45 (3–712) | 51 (3–751) | NS |
Peripheral Blood Blasts (%) | 54 (0–99) | 50 (0–99) | 49 (0–99) | 64 (0–99) | NS |
Lactate Dehydrogenase (U/L)* | 1042 (194–8693) | 997 (291–6711) | 1119 (194–8280) | 1010 (250–8693) | NS |
FAB Category | 0.039 | ||||
M0 | 3 (1) | 0 | 0 | 3 (29) | |
M1 | 83 (27.3) | 33 (32.7) | 18 (17.8) | 32 (31.4) | |
M2 | 110 (36.2) | 33 (32.7) | 42 (41.6) | 35 (34.3) | |
M4 | 84 (27.6) | 29 (28.7) | 34 (33.7) | 21 (20.6) | |
M5 | 16 (5.3) | 4 (4) | 6 (5.9) | 6 (5.9) | |
M6 | 8 (2.6) | 2 (2.0) | 1 (1.0) | 5 (4.9) | |
ELN-2022 risk category | < 0.001 | ||||
Favorable | 137 (45.0) | 76 (75.2) | 44 (43.6) | 17 (16.7) | |
Intermediate | 82 (27.0) | 20 (19.8) | 38 (37.6) | 24 (23.5) | |
Adverse | 85 (28.0) | 5 (5.0) | 19 (18.8) | 61 (59.8) | |
Response of induction | < 0.001 | ||||
Complete remission | 208 (68.4) | 85 (84.2) | 75 (74.3) | 48 (47.1) | |
No response | 96 (31.6) | 16 (15.8) | 26 (25.7) | 54 (52.9) | |
Relapse | 136 (44.7) | 45 (44.6) | 47 (46.5) | 44 (43.1) | NS |
Death during/after induction | 25 (8.2) | 5 (5.0) | 9 (8.9) | 11 (10.8) | NS |
Allogeneic hematopoietic stem cell transplantation | 110 (36.2) | 42 (41.6) | 31 (30.7) | 37 (36.2) | NS |
